Clinical Trial Update: An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU [Phase 2]

View source ↗

Summary

An open-label extension of Phase 2 evaluating the long-term safety and tolerability of the investigational agent LOU064 in adults with chronic spontaneous urtic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• LOU064

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2023-09-29